If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") expected to be issued and outstanding as of June 26, 2026, as described in the Issuer's Prospectus Supplement dated June 25, 2026 and filed with the SEC pursuant to Rule 424(b)(5) on June 26, 2026 (the "Prospectus Supplement") (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 141,119,032 ordinary shares, nominal value Euro 0.04 per share, of the Issuer expected to be issued and outstanding as of June 26, 2026, as described in the Prospectus Supplement (after giving effect to the issuances of shares contemplated therein, which the Prospectus Supplement stated were expected to be completed on June 26, 2026).


SCHEDULE 13D


 
Van Herk Investments B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Van Herk Investments THI B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Van Herk Private Equity Investments B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Stichting Administratiekantoor Penulata
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Van Herk Management Services B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
A. van Herk Holding B.V.
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Stichting Administratiekantoor Abchrys
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
 
Adrianus van Herk
 
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:06/30/2026
Comments accompanying signature:
* Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.